# Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Source: https://onco.cc/trials/nct05948475/  
OnCo record `nct05948475` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tinengotinib in biliary tract cancer, run by TransThera Sciences (Nanjing), Inc., active and no longer recruiting.

## Summary

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma is a phase 3 interventional study registered as NCT05948475 by TransThera Sciences (Nanjing), Inc., with 200 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2026-12. Interventions recorded: Tinengotinib 8 mg, Tinengotinib 10 mg and Physician's Choice.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05948475
- Phase: 3
- Setting: A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
- Sponsor: TransThera Sciences (Nanjing), Inc.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05948475: https://clinicaltrials.gov/study/NCT05948475

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Tinengotinib](https://onco.cc/drugs/tinengotinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05948475.json